Artemisinin resistance in Plasmodium falciparum malaria

Abstract

Background: Artemisinin-based combination therapies are the recommended first-line treatments of falciparum malaria in all countries with endemic disease. There are recent concerns that the efficacy of such therapies has declined on the Thai-Cambodian border, historically a site of emerging antimalarial-drug resistance.

Methods: In two open-label, randomized trials, we compared the efficacies of two treatments for uncomplicated falciparum malaria in Pailin, western Cambodia, and Wang Pha, northwestern Thailand: oral artesunate given at a dose of 2 mg per kilogram of body weight per day, for 7 days, and artesunate given at a dose of 4 mg per kilogram per day, for 3 days, followed by mefloquine at two doses totaling 25 mg per kilogram. We assessed in vitro and in vivo Plasmodium falciparum susceptibility, artesunate pharmacokinetics, and molecular markers of resistance.

Results: We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate-mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P=0.31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco-endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups.

Conclusions: P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)

2009 Massachusetts Medical Society

Figures

Figure 1. Enrollment, Randomization, and Follow-up of the Patients in the Two Studies

Mixed infection was infection with Plasmodium vivax and P. falciparum.

Figure 2. Parasite Clearance Curves

The data are log10-normalized median parasite densities over time among the 20 patients in each treatment group. The T bars indicate half of the interquartile ranges. Artesunate monotherapy consisted of artesunate at a dose of 2 mg per kilogram of body weight for 7 days. Artesunate–mefloquine therapy consisted of artesunate at a dose of 4 mg per kilogram for 3 days followed by mefloquine at a dose of 15 mg per kilogram on day 3 after admission and 10 mg per kilogram on day 4 after admission.

Figure 3. The 50% Inhibitory Concentration (IC50) for Plasmodium falciparum, According to Antimalarial Drug

The panels show the concentrations of chloroquine, mefloquine, dihydroartemisinin, and artesunate resulting in the inhibition of hypoxanthine uptake by 50% after 48 hours of in vitro culture of freshly isolated P. falciparum from the study patients. The horizontal lines are the medians; the I bars represent the interquartile ranges.